| Keywords: |
cancer chemotherapy; treatment response; transplantation, homologous; disease course; neutropenia; review; ascites; diarrhea; drug safety; hypophosphatemia; nonhuman; side effect; antineoplastic agents; alpha interferon; cytarabine; follow up; cancer diagnosis; imatinib; edema; progression free survival; anemia; gastrointestinal symptom; nausea; thrombocytopenia; qt prolongation; nccn clinical practice guidelines; stem cell transplant; hematopoietic stem cell transplantation; in vivo study; antineoplastic activity; drug potency; food and drug administration; in vitro study; dasatinib; chronic myeloid leukemia; drug dose escalation; hyperglycemia; rash; protein kinase inhibitors; heart failure; cardiotoxicity; patient compliance; allogeneic hematopoietic stem cell transplantation; pleura effusion; headache; bcr abl protein; drug blood level; tyrosine kinase inhibitor; nilotinib; amylase blood level; triacylglycerol lipase blood level; pericardial effusion; leukemia, myelogenous, chronic, bcr-abl positive; bilirubin blood level; cytopenia; musculoskeletal disease; chronic myelogenous leukemia; muscle cramp; bcr-abl; nccn guidelines; conception; pregnant woman
|
